Applied Therapeutics, Inc. (APLT)
NASDAQ
Market Cap
$130.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
548 of 963
Rank in Industry
296 of 552
Largest Insider Buys in Sector
APLT Stock Price History Chart
APLT Stock Performance
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Insider Activity of Applied Therapeutics, Inc.
Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $0 and sold $9.36M worth of Applied Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $820,285 and sold $8.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.
List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.
| 2024-08-22 | Sale | Chief Medical Officer | 22,681 0.0206% | $5.83 | $132,230 | +44.55% | ||
| 2024-08-22 | Sale | Chief Financial Officer | 13,530 0.0123% | $5.83 | $78,880 | +44.55% | ||
| 2024-08-14 | Sale | President and CEO | 119,591 0.1056% | $5.93 | $709,175 | 0.00% | ||
| 2024-08-13 | Sale | President and CEO | 357,423 0.3288% | $6.18 | $2.21M | 0.00% | ||
| 2024-08-12 | Sale | President and CEO | 300,000 0.267% | $5.98 | $1.79M | +34.82% | ||
| 2024-06-06 | Sale | President and CEO | 61,795 0.0519% | $4.32 | $266,954 | +33.56% | ||
| 2024-06-06 | Sale | Chief Medical Officer | 22,003 0.0185% | $4.32 | $95,053 | +33.56% | ||
| 2024-06-06 | Sale | Chief Financial Officer | 16,980 0.0143% | $4.32 | $73,354 | +33.56% | ||
| 2024-06-05 | Sale | 10 percent owner | 150,000 0.1261% | $4.24 | $636,000 | +35.18% | ||
| 2024-06-04 | Sale | 10 percent owner | 150,000 0.131% | $4.21 | $631,500 | +41.09% | ||
| 2024-03-14 | Sale | President and CEO | 318,573 0.2652% | $5.39 | $1.72M | -2.92% | ||
| 2024-03-14 | Sale | Chief Medical Officer | 110,804 0.0922% | $5.39 | $597,234 | -2.92% | ||
| 2024-03-14 | Sale | Chief Commercial Officer | 48,871 0.0407% | $5.39 | $263,415 | -2.92% | ||
| 2024-03-14 | Sale | Chief Financial Officer | 28,727 0.0239% | $5.39 | $154,839 | -2.92% | ||
| 2023-12-01 | director | 30,000 0.0358% | $2.18 | $65,367 | +114.11% | |||
| 2023-11-30 | Sale | President and CEO | 3,968 0.0048% | $1.97 | $7,817 | +147.60% | ||
| 2023-11-30 | Sale | Chief Medical Officer | 1,583 0.0019% | $1.97 | $3,119 | +147.60% | ||
| 2023-11-30 | Sale | Chief Commercial Officer | 965 0.0012% | $1.97 | $1,901 | +147.60% | ||
| 2023-11-03 | Sale | 10 percent owner | 143,450 0.2215% | $2.31 | $331,370 | +100.00% | ||
| 2023-11-02 | Sale | 10 percent owner | 103,808 0.1662% | $2.32 | $240,835 | +104.76% |
Insider Historical Profitability
10.44%
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 5855077 5.032% | $1.13 | 2 | 6 | +18.45% |
| Shendelman Shoshana | President and CEO | 4690839 4.0315% | $1.13 | 6 | 15 | +32.1% |
| Perfetti Riccardo | Chief Medical Officer | 986853 0.8481% | $1.13 | 1 | 59 | <0.0001% |
| Hansard Adam | Chief Commercial Officer | 732919 0.6299% | $1.13 | 0 | 5 | |
| Funtleyder Leslie D. | Chief Financial Officer | 277911 0.2388% | $1.13 | 0 | 20 | |
| MARCUS JOEL S | director | 365360 0.314% | $1.13 | 2 | 3 | +10.6% |
| Silberstein Charles | Chief Financial Officer | 87803 0.0755% | $1.13 | 0 | 1 | |
| Kanter Stacy J. | director | 63000 0.0541% | $1.13 | 3 | 0 | <0.0001% |
| Mahadevan Chids | See Remarks | 9800 0.0084% | $1.13 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Franklin Templeton Investments | $71.84M | 9.24 | 10.56M | +50.53% | +$24.12M | 0.02 | |
| Vr Adviser Llc | $61.71M | 7.94 | 9.07M | +45.2% | +$19.21M | 3 | |
| Perceptive Advisors | $54.43M | 7.01 | 8.01M | +96.19% | +$26.69M | 0.04 | |
| Janus Henderson | $43.56M | 5.61 | 6.41M | +198.57% | +$28.97M | 0.02 | |
| Tupelo Capital Management LLC | $37.91M | 4.88 | 5.57M | +1.83% | +$679,999.99 | 0.93 | |
| Morgan Stanley | $21.72M | 2.8 | 3.19M | +5,856.5% | +$21.35M | <0.01 | |
| The Vanguard Group | $20.47M | 2.63 | 3.01M | -6.82% | -$1.5M | <0.0001 | |
| Simplify Asset Management Inc | $19.16M | 2.47 | 2.82M | +16.55% | +$2.72M | 1.85 | |
| Adage Capital Partners Gp L L C | $18.02M | 2.32 | 2.65M | New | +$18.02M | 0.03 | |
| Tang Capital Management, LLC | $15.16M | 1.95 | 2.23M | New | +$15.16M | 0.06 | |
| Frazier Life Sciences Management L P | $13.28M | 1.71 | 1.95M | New | +$13.28M | 0.6 | |
| Parkman Healthcare Partners Llc | $12.61M | 1.62 | 1.85M | +81.99% | +$5.68M | 1.57 | |
| Schonfeld Group | $12.49M | 1.61 | 1.84M | +273.69% | +$9.15M | 0.07 | |
| Opaleye Management Inc | $12.04M | 1.55 | 1.77M | +62.01% | +$4.61M | 2.66 | |
| Soleus Capital Management, L.P. | $10.64M | 1.37 | 1.56M | +239.61% | +$7.51M | 0.04 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $10.19M | 1.31 | 1.5M | +67.33% | +$4.1M | 0.27 | |
| Laurion Capital Management LP | $10.07M | 1.3 | 1.48M | +243.62% | +$7.14M | 0.07 | |
| Alyeska Investment Group L P | $9.77M | 1.26 | 1.44M | -44.6% | -$7.87M | 0.06 | |
| Logos Global Management Lp | $8.98M | 1.18 | 1.35M | -18.68% | -$2.06M | 0.97 | |
| Artal Group S A | $6.86M | 0.88 | 1.01M | New | +$6.86M | 0.03 | |
| BlackRock | $6.73M | 0.87 | 989,277 | +87.4% | +$3.14M | <0.0001 | |
| Millennium Management LLC | $6.3M | 0.81 | 926,425 | +54.39% | +$2.22M | <0.01 | |
| ACUTA CAPITAL PARTNERS LLC | $5.39M | 0.69 | 792,000 | +50.83% | +$1.81M | 3.5 | |
| Goldman Sachs | $4.86M | 0.63 | 715,208 | +4,169.39% | +$4.75M | <0.01 | |
| Deutsche Bank | $4.23M | 0.55 | 622,227 | New | +$4.23M | <0.01 | |
| Sphera Fund | $4.21M | 0.54 | 619,029 | New | +$4.21M | 0.03 | |
| Geode Capital Management | $4.11M | 0.53 | 604,428 | +4.63% | +$182,001.81 | <0.0001 | |
| Invesco | $3.67M | 0.47 | 539,857 | New | +$3.67M | <0.01 | |
| Susquehanna International Group | $3.3M | 0.42 | 484,885 | -14.55% | -$561,408.00 | <0.01 | |
| Qube Research & Technologies | $3.12M | 0.4 | 459,141 | +137.07% | +$1.81M | <0.01 | |
| Walleye Capital | $2.1M | 0.27 | 308,316 | +1,713.62% | +$1.98M | 0.01 | |
| Jane Street Capital | $1.66M | 0.21 | 244,612 | +85.44% | +$766,400.52 | <0.01 | |
| State Street | $1.41M | 0.18 | 206,669 | +46.92% | +$448,799.94 | <0.0001 | |
| Squarepoint Ops LLC | $1.32M | 0.17 | 193,758 | +1,292.44% | +$1.22M | 0.01 | |
| JPMorgan Chase | $1.22M | 0.16 | 178,924 | +281.23% | +$897,538.65 | <0.0001 | |
| Renaissance Technologies | $1.2M | 0.15 | 175,800 | -73.08% | -$3.24M | <0.01 | |
| Bridgeway Capital Management | $1.18M | 0.15 | 173,800 | -10.32% | -$136,000.00 | 0.02 | |
| Cubist Systematic Strategies | $1.11M | 0.14 | 163,072 | +178.29% | +$710,430.26 | 0.01 | |
| Two Sigma | $1.06M | 0.14 | 155,158 | -45.75% | -$889,704.86 | <0.01 | |
| Man Group Plc | $1.05M | 0.14 | 154,636 | -7.15% | -$81,015.21 | <0.01 | |
| UBS | $1.04M | 0.13 | 152,760 | +27.08% | +$221,360.19 | <0.0001 | |
| Rockefeller Capital Management L P | $1.02M | 0.13 | 150,000 | New | +$1.02M | <0.01 | |
| J. Goldman & Company | $995,466.00 | 0.13 | 146,392 | New | +$995,466.00 | 0.04 | |
| Citigroup | $807,867.00 | 0.1 | 118,804 | -45.98% | -$687,629.43 | <0.01 | |
| Northern Trust | $723,880.00 | 0.09 | 106,453 | -0.14% | -$979.20 | <0.0001 | |
| Hrt Financial Llc | $672,000.00 | 0.09 | 98,879 | New | +$672,000.00 | <0.01 | |
| Eam Investors | $631,530.00 | 0.08 | 92,872 | -49.21% | -$611,986.79 | 0.04 | |
| OMERS | $439,960.00 | 0.06 | 64,700 | +393.89% | +$350,880.00 | 0.01 | |
| Barclays | $417,000.00 | 0.05 | 61,272 | New | +$417,000.00 | <0.0001 | |
| Richmond Brothers, Inc. | $420,424.00 | 0.05 | 61,827 | -50% | -$420,424.00 | 0.78 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.